WILMINGTON, Del. – InSilicoTrials, a health tech company specializing in AI-driven simulation technologies for drug development, has been selected to join the Microsoft for Startups Pegasus Program. The invitation-only initiative is designed to accelerate the growth of high-potential startups by connecting them with Microsoft’s global sales channels, enterprise customer base, and advanced cloud infrastructure.
This marks a key milestone in InSilicoTrials’ efforts to transform the healthcare R&D landscape through digital tools, including in silico trials and virtual patient simulations. By leveraging Microsoft Azure, the company aims to scale its platform, expand global reach, and provide pharmaceutical companies, biotech firms, and researchers with more efficient ways to design clinical trials and develop new therapies.
“InSilicoTrials is focused on expanding access to simulation and AI tools that help life sciences organizations de-risk faster development of safer, more effective treatments,” said Luca Emili, CEO of InSilicoTrials. “Joining the Pegasus Program allows us to deepen our integration with Microsoft Azure and bring the benefits of our in silico technologies to a wider customer base.”
InSilicoTrials’ platform includes digital twin models, AI-based simulations, and synthetic patient populations designed to speed up R&D timelines while reducing reliance on traditional clinical trials. The tools also aim to lower development costs and improve safety and efficacy assessments in early-stage drug development.
Through the Pegasus Program, InSilicoTrials will gain access to co-selling opportunities, joint go-to-market initiatives, and the ability to offer its services via the Microsoft Azure Marketplace—making it easier for enterprise customers to adopt its simulation-based solutions.
Sally Ann Frank, Global Lead for Health & Life Sciences at Microsoft for Startups, welcomed the partnership. “We’re excited to support InSilicoTrials as they bring cutting-edge AI and digital simulation tools to life sciences organizations,” she said. “Their technology has the potential to transform healthcare innovation and accelerate drug development on a global scale.”
The partnership underscores the growing role of AI and cloud-based tools in shaping the future of medical research, with InSilicoTrials positioned to be a key player in that transformation.
